Gastrointestinal stromal tumour (GIST) is the most common sarcoma of the digestive tract \[[@CIT0001]\]. Approximately 95% of GISTs express KIT, the receptor for the stem cell factor \[[@CIT0002]\]. *KIT* mutations frequently result in KIT phosphorylation and constitutive activation. In a few GISTs (5--10%) a mutation is found in the gene encoding the platelet-derived growth factor receptor alpha (*PDGFRA*). Both KIT and PDGFRA receptors are tyrosine kinases and key players in GIST tumourigenesis \[[@CIT0003]\]. By the introduction of the tyrosine kinase inhibitor (TKI) imatinib, a selective inhibitor of KIT, PDGFRA and a few other kinases, a new era in the management of GIST began \[[@CIT0004],[@CIT0005]\]. Most patients with advanced GIST respond to imatinib, the standard first-line treatment, but the majority eventually progress with the median time to imatinib resistance being approximately two years \[[@CIT0005]\]. In acquired imatinib resistance secondary mutations in *KIT* exons 13 and 17 are common resulting in a kinase conformation that prohibits imatinib from binding to the kinase \[[@CIT0006]\].

A metabolic response to imatinib in GIST may be observed early with 2-deoxy-2-\[^18^F\]fluoro-D-glucose (^18^F-FDG) positron emission tomography (PET) \[[@CIT0004]\], sometimes even within a few hours after starting imatinib \[[@CIT0007],[@CIT0008]\]. Dynamic ^18^F-FDG PET enables assessment of tissue uptake of the tracer in space and time following injection and may offer valuable information about tumour vascularisation and its metabolic characteristics \[[@CIT0009]\].

Human tumour xenografts are useful for evaluating novel therapeutic agents, since tumour vascular and stromal components cannot be addressed *in vitro*. The GIST human xenograft model AHAX \[[@CIT0010]\] originates from a patient with a clinically imatinib-resistant GIST harbouring a primary *KIT* exon 11 mutation (sensitive to imatinib) and a secondary *KIT* exon 17 mutation (likely treatment-induced mutation). Since *KIT* exon 11 is the most common site of mutation in primary GIST and *KIT* exon 17 is the most frequent site of a secondary resistance mutation \[[@CIT0011]\], this model reflects the most common clinical scenario in imatinib-resistant GIST.

Imatinib, administered usually continuously at a dose of 400 mg/day, is generally well tolerated and despite prior tumour progression during first-line imatinib it is often considered as the last-line palliative systemic treatment for patients with advanced GIST \[[@CIT0012]\]. This practice is, however, controversial in the absence of other than anecdotal supportive clinical experiences. A randomised clinical trial is currently comparing imatinib plus the best supportive care to the latter alone as palliative treatment of advanced GIST (ClinicalTrials.gov identifier NCT1151852). Somewhat unexpectedly withdrawal of imatinib in responding patients and reinstitution of imatinib at the time of metastatic progression, did not affect survival in a large randomised clinical trial \[[@CIT0013],[@CIT0014]\].

The aim of the present study was to evaluate the potential benefits of continuous and intermittent imatinib administration in an experimental human GIST xenograft model harbouring imatinib resistance mutation. This was evaluated by tumour growth measurements and assessment of tumour metabolic activity (with dynamic ^18^F-FDG PET), mitotic rate, and expression of HIF-1α, caspase-3 and GLUTs.

Material and methods {#ss2}
====================

Animals and xenografts {#ss3}
----------------------

Human GIST AHAX xenografts with a mutation in *KIT* exon 11 (c.1673_1687del, p.Lys558_Glu562del) and *KIT* exon 17 (c.2446G\> C, p.Asp816His) \[[@CIT0010]\] were established by subcutaneous implantation of tumour tissue fragments (˜2 × 2× 2 mm^3^) bilaterally into NCR athymic mice. The mice were kept under specific pathogen-free conditions at a constant temperature (22--24°C) and humidity (55--60%), and were given sterilised food and tap water ad libitum.

Six weeks after implantation 37 mice were randomly allocated into a control group (n = 12) or to one of two imatinib treatment groups, where imatinib was administrated either continuously (n = 13) or intermittently (n = 12, one week on and one week off). The study was approved by the Institutional Committee on Research on Animal Care and was performed according to Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Marketing and Education (New York Academy of Science, New York, NY, USA).

Tumour volume measurements {#ss4}
--------------------------

Tumour size was measured by a caliper twice weekly from the date of implantation. Tumour volume was calculated using the modified ellipsoid formula \[[@CIT0015]\], where the volume *V*(mm^3^) = (л/6)× *a*(mm)× b^2^(mm^2^), *a* and *b* being the longest and the perpendicular tumour diameters, respectively. The measurements were normalised to individual pre-treatment (day 0) tumour volumes. Estimated tumour volume doubling time was calculated using linear regression on ln-transformed normalised tumour volumes.

Imatinib administration {#ss5}
-----------------------

Imatinib (Glivec^®^, Novartis Pharma GmbH, Basel, Switzerland) was dissolved in distilled water and given by oral gavage: either 100 mg/kg once daily (the continuous treatment group) or in two-week cycles, with imatinib given daily for seven days followed by placebo (water) for seven days (the intermittent treatment group). The control group received water only by oral gavage. The duration of the experiment was 91 days.

Dynamic ^18^F-FDG PET imaging {#ss6}
-----------------------------

Four mice from each of the three groups underwent dynamic ^18^F-FDG PET one day prior to sacrifice, using a small animal PET scanner (microPET Focus 120, Siemens Medical Solutions, Erlangen, Germany). Following overnight fasting the mice were anesthetised and given an *i.v.* bolus injection of 7--10 MBq ^18^F-FDG (GE Healthcare AS, Oslo, Norway) diluted in heparinised saline \[[@CIT0007]\]. Acquisition of list-mode data started prior to ^18^F-FDG injection and lasted for 50 minutes post-injection. The dynamic PET images were reconstructed using OSEM-MAP \[[@CIT0016],[@CIT0017]\] producing images with a voxel size of 0.87 × 0.87 × 0.80 mm^3^. The reconstructed time frames were 10 seconds during the initial 1.5 minutes followed by reduced temporal resolution for the remaining frames. Kinetic modeling of the DICOM-images was performed using in-house written IDL-programs (Interactive Data Language, v6.2, Research Systems Inc., Boulder, CO, USA). Briefly, the mean time activity curves (TACs) for each tumour were calculated and normalised to individual arterial input functions (AIFs) to account for differences in the injected ^18^F-FDG activity between the animals \[[@CIT0009]\].

A three-compartment model consisting of a blood compartment and two sequential tissue compartments was used to evaluate the ^18^F-FDG kinetics. The concentration in tissue (*C* ~*T*~) is assumed to be separated into a free (non-metabolised) and a bound (metabolised) compartment with tracer concentrations of *C* ~*F*~ and *C* ~*B*~, respectively ([Figure 1](#F1){ref-type="fig"}). The exchange of ^18^F-FDG between the two tissue compartments is described by the rate constants *k* ~1~, *k* ~2~, *k* ~3~, and *k* ~4~ \[min^−1^\], where *k* ~1~ includes perfusion, vascular permeability and the binding of ^18^F-FDG to the GLUT receptors, *k* ~2~ the clearance of ^18^F-FDG back into the blood, *k* ~3~ the cellular internalisation, and *k* ~4~ the cellular externalisation. The kinetic parameters were estimated by fitting the TAC to this model and non-linear least squares minimisation. *k* ~4~ was assumed to be low, and was set to zero in the calculations. The blood volume fraction (*v* ~*B*~) was estimated as described previously \[[@CIT0018]\]. The metabolic rate of ^18^F-FDG (*MR* ~*FDG*~) was defined as (*k* ~1~∙*k* ~3~)/(*k* ~2~ + *k* ~3~). The fit between the measured TACs and the curves obtained from modeling were evaluated by calculating correction coefficients (*r* ^2^) for each tumour voxel.

![The three-compartment model used for extracting pharmacokinetic information from dynamic ^18^F-FDG PET. *C* ~*P*~ is the concentration of ^18^F-FDG in plasma, and the tissue concentration *C* ~*T*~ is composed of non-metabolized, or free, ^18^F-FDG CF, and metabolized, or bound, ^18^F-FDG, CB. *C* ~*T*~ is further separated into not metabolised or free ^18^F-FDG, *C* ~*F*~, and metabolised or bound ^18^F-FDG, *C* ~*B*~. The kinetic parameters *k* ~1~ (min^−1^) and *k* ~2~ (min^−1^) describe the forward and backward ^18^F-FDG diffusion, respectively. The *k* ~3~ (min^−1^) and *k* ~4~ (min^−1^) parameters signify the rates of ^18^F-FDG phosphorylation and dephosphorylation, respectively, i.e., reflecting protein binding or glucose metabolism.](ONC-52-776-g001){#F1}

Histopathology and immunohistochemistry {#ss7}
---------------------------------------

At the end of the experiment the mice were sacrificed by neck dislocation and tumour sites were matched with the in vivo imaging slices. The xenografts were excised and divided in two; one half was snap-frozen in liquid nitrogen and stored at °80°C, while the second half was formalin-fixed and paraffin-embedded.

The paraffin-embedded sections were stained using a standard method (Dako EnVisionTM+ System, Peroxidase (DAB) (K4011, Dako, Glostrup, Denmark) and a Dako Autostainer). The primary antibodies, dilutions, pH retrieval solution and the positive controls are listed in [Table I](#T1){ref-type="table"}. The proportion of positively staining tumour cells was assessed semiquantitatively as absent (0, no immunostaining), slight (1, \< 10% of tumour cells were stained), moderate (2, 10--50% of cells showed staining), or strong (3, \> 50% of cells were stained). The intensity of staining was recorded as absent (0), weak (1), moderate (2) or strong (3). A staining score was obtained by multiplying these two values. The mitotic index was counted per 20 high power fields (HPFs) using a Leica DM2500 microscope (Leica Microsystems CMS, Germany) with an objective × 40 giving an area of 0.31 mm^2^ for a single HPF.

###### 

The primary antibodies used for immunohistochemistry.

  Antibody target   Company                                               Catalogue number   Dilution   Retrieval solution pH[\*](#TFN1){ref-type="table-fn"}   Positive control
  ----------------- ----------------------------------------------------- ------------------ ---------- ------------------------------------------------------- ---------------------
  GLUT-1            Abcam, Cambridge, UK                                  Ab652              1:200      Low pH                                                  Kidney cancer
  GLUT-2            Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA   Sc-9117            1:100      Low pH                                                  Pancreas
  GLUT-3            Abcam, Cambridge, UK                                  Ab53095            1:200      High pH                                                 Testis
  GLUT-4            AbD Serotec, Oxford, UK                               4670-1704          1:1000     High pH                                                 Salivary gland
  HIF-1α            Novus Biologicals, Cambridge, UK                      NB100--499         1:300      High pH                                                 Placenta
  Caspase-3         Cell Signaling Technology, Danvers, MA, USA           9664               1:100      High pH                                                 Large cell lymphoma

\*Low pH: citrate buffer, pH 6.1 (K8005, Dako, Glostrup, Denmark). High pH: Tris/EDTA, pH 9 (K8004, Dako, Glostrup, Denmark).

KIT and PDGFRA mutation analysis {#ss8}
--------------------------------

Genomic DNA was extracted from 10 AHAX xenografts. Thirty nanograms of DNA was amplified using Phusion^®^ Hot Start DNA polymerase and Phusion GC buffer (Finnzymes, Espoo, Finland). The thermal cycling conditions were DNA denaturation at 98°C for 30 seconds, five cycles at 98°C for 10 seconds, 65°C for 15 seconds and 72°C for 10 seconds, followed by 35 similar cycles where the annealing temperature was reduced to 60°C. Final extension was allowed at 72°C for 1 minute (The forward and reverse PCR primer pairs used can be provided upon request). The sequencing reactions were performed in two directions using the BigDye^®^ Terminator v1.1 Cycle Sequencing Kit (Life Technologies, Carlsbad, CA, USA). The sequencing products were run on an automatic capillary sequencer (3130xl Genetic Analyzer, Life Technologies, Paisley, UK).

Statistical analysis {#ss9}
--------------------

Statistical analyses were performed using Excel^®^ (Microsoft Corporation, Redmond, WA, USA) and SPSS version 18.0 (SPSS Science, Chicago, IL, USA). Non-Gaussian distributions were compared using the non-parametric Mann-Whitney U-test. Two-sided t-test was used to compare the first order least-square linear regression estimated tumour doubling times. Significance was set to 5%.

Results {#ss10}
=======

Tumour growth {#ss11}
-------------

Tumour growth was observed in 70 (95%) of the 74 implants in the 37 mice. One mouse was sacrificed prematurely because of oesophageal perforation and was excluded from the study. The tumour volumes did not differ significantly between the three groups prior to therapy, with a median pretreatment tumour volume of 120 mm^3^ (range; 22--340 mm^3^, SE; ± 73 mm^3^). The normalised tumour volume growth curves are shown in [Figure 2](#F2){ref-type="fig"}. The tumour volume doubling time in the control group was 24.7 days (95% CI 21.9--28.4 days). The tumour doubling time was significantly shorter in the intermittent imatinib group (47.4 days; 95% CI 40.6--56.9 days) compared to the continuous group (130.9 days; 95% CI 84.2--293.5 days; p \< 0.001). Both treatment groups showed significantly longer tumour volume doubling times compared to the untreated tumours (p \< 0.001).

![Normalised tumour volume growth of the human GIST AHAX xenograft in mice receiving either imatinib (100 mg/kg/day) continuously, intermittently (one week on, one week off) or placebo (water). At the end of experiment, mice with particularly large tumours were scarified, causing a dip in tumour volume growth (the light grey symbols). The data are given as means and standard errors of the means.](ONC-52-776-g002){#F2}

Dynamic ^18^F-FDG PET {#ss12}
---------------------

^18^F-FDG PET of the treated animals was performed after 88 days of treatment, at a time point where both treatment groups were receiving imatinib. [Figure 3A](#F3){ref-type="fig"} shows a series of ^18^F-FDG PET images demonstrating tracer uptake in a flank tumour in the continuous imatinib group. The TACs from the tumours treated with intermittent imatinib showed higher uptake and reached a plateau earlier after tracer injection as compared to the tumours treated with continuous imatinib (25 minutes vs. 30 minutes, respectively). The median area under the normalised TAC curve was 20% higher for the intermittent group, albeit not significantly different (p = 0.08) (data not shown).

![An example of cumulative ^18^F-FDG uptake with time in a human GIST AHAX xenograft model (A). The white arrows point at the tumour. ^18^F-FDG uptake as a function of time for two selected voxels within the xenograft is shown in (B). The uptake curves for the free and bound ^18^F-FDG components obtained from kinetic modeling are provided.](ONC-52-776-g003){#F3}

TACs of two voxels located at different sites within a continuous imatinib-treated xenograft are shown in [Figure 3B](#F3){ref-type="fig"}. Using kinetic modeling, the TAC of the voxels were separated into free (not metabolised) and bound (metabolised) components. The goodness of fit between the measured TACs and the uptake curves obtained from modeling ranged from 0.91 to 0.98 with no significant differences between the two treatment groups. Mean *k* ~1~, *k* ~2~, *k* ~3~, *MR* ~*FDG*~ and *v* ~*B*~ for both treatment groups are summarised in [Table II](#T2){ref-type="table"}. Significant differences were found for the kinetic parameters *k* ~1~, *k* ~3~ and *MR* ~*FDG*~. The influx *k* ~1~ parameter was 32% higher in the intermittent group (p = 0.01), while *k* ~3~ and *MR* ~*FDG*~ were 95% (p = 0.01) and 50% (p = 0.03) higher in the continuous treatment group, respectively. No significant correlations were found between the tumour volumes and the tumour pharmacokinetic parameters.

###### 

Results from pharmacokinetic modelling of dynamic ^18^F-FDG PET data. Data are given as median values.

                           Treatment group           
  ------------------------ ----------------- ------- -------
  *k* ~1~ (min^−1^)        0.066             0.050   0.005
  *k* ~2~ (min^−1^)        0.100             0.087   0.386
  *k* ~3~ (min^−1^)        0.007             0.013   0.011
  *MR* ~*FDG*~ (min^−1^)   0.004             0.006   0.028
  *v* ~*B*~                0.007             0.002   0.149

*k* ~1~, *k* ~2~ and *k* ~3~ are the kinetic rate constants from the three-compartment model shown in [Figure 1](#F1){ref-type="fig"}; *MR* ~*FDG*~, the metabolic rate of ^18^F-FDG; *v* ~*B*~, the estimated blood volume.

\*p for the difference between the intermittent and continuous imatinib groups.

Tumour histology and immunohistochemistry {#ss13}
-----------------------------------------

Microscopic examination of the haematoxylin stained tumour sections revealed no differences in tumour morphology between the three groups. However, the mitotic index was significantly higher in the control group (median; 13 mitoses/20 HPFs) as compared to the continuous and the intermittent group (both medians 4/20 HPFs, p = 0.02). The cytoplasmic GLUT-1 expression was significantly higher in the control group as compared to the intermittent group (median score 9 vs. 6; p = 0.023) and the continuous group (median score 6; p = 0.009). Both treatment groups had a significantly higher expression of cytoplasmic GLUT-2 (both median scores 9) than the control group (median score 3; p \< 0.001). The expression of both the cytoplasmic and the membranous form of GLUT-3 were significantly higher (p \< 0.001) in xenografts treated with intermittent imatinib (median score 3 and 3, respectively) as compared to xenografts treated with continuous imatinib (median score 0 and 0, respectively). There were no differences between the three groups with respect to HIF-1α or caspase-3 expression (data not shown).

KIT and PDGFRA mutations {#ss14}
------------------------

Ten xenografts (continuous group, 4; intermittent group, 3; control group, 3) were analysed for *KIT* and *PDGFRA* mutations to investigate tumour mutation status at the end of the experiment. Sequencing confirmed that all xenografts had maintained the original mutation in *KIT* exon 11 (c.1673_1687del, p.Lys558_Glu562del) and in *KIT* exon 17 (c.2446G\> C, p.Asp816His). No further mutations were detected in *KIT* exons 9, 14 or 17, or in *PDGFRA* exons 12, 14 or 18.

Discussion {#ss15}
==========

We explored the effects of imatinib administered either intermittently or continuously in a human GIST xenograft harbouring the D816H mutation, which is a mutation considered to cause clinical imatinib resistance in GIST patients. The results show that the tumours do not regress either with intermittent or continuous imatinib, but, notably, they grow at a substantially slower rate than untreated tumours. This finding suggests that GISTs with a *KIT* 11 deletion mutation coupled with a D816H substitution mutation are not entirely imatinib-resistant. From a clinical point of view this is potentially an important observation, since the *KIT* exon 11 deletion mutation is the most common mutation in GIST, and exon 17 point mutations are the most frequent mutations considered to confer imatinib resistance. In clinical practice, imatinib administration is often discontinued when advanced GIST stops to respond to imatinib, and alternative treatments such as sunitinib or other TKIs are instituted. Anecdotal clinical experience suggests that reinstitution of imatinib after failure of the second- or third-line TKI treatments may still slow down GIST progression compared to no systemic treatment. Although firm clinical evidence is lacking, reinstitution of imatinib may still be advantageous as the last-line palliative care \[[@CIT0012]\].

The reason for imatinib benefit in the presence of D816H remains hypothetical. The *KIT* exon 11 deletion mutation, unlike the D816H mutation, continues to be sensitive to imatinib, which may results in a less active KIT kinase in the presence of imatinib as compared to a kinase where both mutations are uninhibited. If this hypothesis is correct, the present findings may have relevance to many GISTs with an imatinib-sensitive primary mutation and an imatinib-insensitive secondary mutation. The original primary mutation is virtually always present in GISTs that contain a secondary resistance mutation \[[@CIT0011]\]. Of note, more than one secondary mutation are commonly found in tumours that grow during imatinib treatment, sometimes even within the same metastasis \[[@CIT0019]\]. Our findings may thus lend support to rechallenge with imatinib, even in cases when multiple secondary resistance mutations are present, provided that the primary mutation is imatinib-sensitive.

The French Sarcoma Group investigated in the randomised BRF14 trial the effect of interrupting imatinib treatment at after either one, three or five years of treatment in patients with advanced GIST who continued to respond to imatinib. Interruption of imatinib resulted in rapid GIST progression in the majority of patients, but almost all patients responded to imatinib reinstitution. No overall survival difference was seen between the interruption and the continuation groups, regardless of the timing of imatinib interruption \[[@CIT0013],[@CIT0014]\]. Rapid cycling of imatinib administration (one week on, one week off) has not been tested in clinical trials, but the present result showed no benefits during the 91-day observation period.

The AHAX xenograft model of human GIST has proven useful for studying ^18^F-FDG uptake responses to TKIs \[[@CIT0007]\]. In the current study we found differences in the dynamic ^18^F-FDG uptake characteristics between the intermittent and the continuous treatment groups imaged while the mice were on imatinib. The TAC amplitude was higher in the intermittent group indicating either increased perfusion and/or increased metabolism compared to the continuous group. The tumour metabolic rate (*MR* ~*FDG*~), in turn, was higher in the continuous group, whereas *k* ~1~ was higher and *k* ~3~ lower in the intermittent group as compared to the continuous group suggesting presence of more perfusion, vascular permeability or vascular damage (high flow, leaky vessels) in the intermittent group \[[@CIT0020]\]. Lack of correlations between tumour volumes and kinetic parameters indicate that tumour size could not explain the observed differences in FDG uptake. Taken together, these findings suggest that the schedule of imatinib administration influences tumour glucose uptake and metabolic rate. This observation should, however, be interpreted with some caution, since only four mice from each group underwent dynamic PET and the tumours showed heterogeneity in the PET parameters.

The GLUTs play a central role in the accumulation of ^18^F-FDG within tumour cells. GLUT-1 is present in most cell types and is a key factor in glucose uptake, but different cancers express different GLUTs \[[@CIT0021],[@CIT0022]\]. We found a difference in GLUT-3 expression between the two treatment groups. GLUT-3 is expressed in neurons and was originally designated as the neuronal GLUT. GISTs may show both muscle and neuronal differentiation and GLUT-3 expression may in part be related to rapid ^18^F-FDG uptake in GISTs \[[@CIT0023]\]. Imatinib induces GLUT translocation from the plasma membrane to the cytosol via endocytosis \[[@CIT0024],[@CIT0025]\]. In line with this, we found higher cytoplamic GLUT-2 expression in both imatinib groups compared to the control group.

In conclusion, the present study suggests that continuation of imatinib treatment may still benefit some GIST patients despite presence of an imatinib resistance mutation, such as D816H. In this setting, imatinib may slow down tumour progression, possibly by inhibiting the imatinib-sensitive primary mutation. Both continuous imatinib administration and the alternating one week on -- one week off administration slowed down tumour progression, but the tumour growth was significantly more rapid with the alternating scheme. We found differences in ^18^F-FDG uptake kinetics and tumour ^18^F-FDG metabolic rate between the continuous and the intermittent imatinib administration groups, but their clinical significance remains unknown.
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